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Abstract: This study examines the associations between medication adherence and burden,
and health-related quality of life (HRQOL) in predialysis chronic kidney disease (CKD).
A prospective study targeting adults with advanced CKD (estimated glomerular filtration rate (eGFR)
< 30 mL/min/1.73 m2) and not receiving renal replacement therapy was conducted in Tasmania,
Australia. The actual medication burden was assessed using the 65-item Medication Regimen
Complexity Index, whereas perceived burden was self-reported using a brief validated questionnaire.
Medication adherence was assessed using a four-item Morisky-Green-Levine Scale (MGLS) and the
Tool for Adherence Behaviour Screening (TABS). The Kidney Disease and Quality of Life Short-Form
was used to assess HRQOL. Of 464 eligible adults, 101 participated in the baseline interview and 63
completed a follow-up interview at around 14 months. Participants were predominantly men (67%),
with a mean age of 72 (SD 11) years and eGFR of 21 (SD 6) mL/min/1.73 m2. Overall, 43% and 60%
of participants reported medication nonadherence based on MGLS and TABS, respectively. Higher
perceived medication burden and desire for decision-making were associated with nonadherent
behaviour. Poorer HRQOL was associated with higher regimen complexity, whereas nonadherence
was associated with a decline in physical HRQOL over time. Medication nonadherence, driven by
perceived medication burden, was prevalent in this cohort, and was associated with a decline in
physical HRQOL over time.
Keywords: chronic kidney disease; medication adherence; health-related quality of life; medication
regimen complexity index; medication burden
1. Introduction
Medication adherence is the primary determinant of treatment success, yet 43% to 78% of people
receiving medications for chronic diseases are nonadherent to medical treatment. [1] The reported
prevalence of medication nonadherence in chronic kidney disease (CKD) also varies considerably;
12%–53% in stage 3 to 4 CKD and 21%–74% in end-stage kidney disease (ESKD) [2–4]. Medication
adherence is particularly relevant in people with CKD, given its potential importance in slowing
disease progression and, therefore, improving health outcomes. Poor adherence to antihypertensive
medications in CKD, reported in nearly one-third of patients, is associated with uncontrolled
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hypertension [5,6]. Research also indicates that nonadherence to cardiovascular medications at
the predialysis stage is an independent predictor of post-dialysis mortality in people with advanced
CKD [7].
Patient-centred outcomes, such as health-related quality of life (HRQOL), are important measures
that capture patients’ perspectives and experiences about their functionality and wellbeing [8]. These
outcome measures are particularly relevant in patients with advanced CKD, as they inform treatment
goals and modalities [9]. Nevertheless, there is limited data on patient-centred outcomes in people
with advanced CKD [9–11], particularly in those not receiving renal replacement therapy [12]. More
importantly, the relationship between HRQOL and medication-related factors, such as medication
burden and adherence, is relatively under-examined in this patient group [13].
The actual and perceived medication burden can be assessed in different ways, including the
complexity of medication regimens and the number of medications used. Medication regimen
complexity and the number of medications would be expected to influence adherence, although
the findings on this subject are not consistent [14]. In patients with CKD, the association between
medication regimen complexity and adherence is inconclusive [10,11]. Moreover, despite the high
medication burden in patients with advanced CKD, evidence is lacking on medication-related factors
and patient-centred outcomes in predialysis CKD.
This study aimed to (i) identify factors associated with medication burden (perceived and actual),
(ii) examine the association between medication burden (actual and perceived) and adherence in adults
with predialysis CKD, (iii) examine the association between HRQOL and actual medication burden,
and (iv) evaluate the relationship between medication adherence and change in HRQOL over time.
2. Materials and Methods
2.1. Study Design and Population
This analysis utilised data from the Tasmanian CKD study, a prospective cohort of Tasmanian
adults aged ≥18 years with advanced CKD (based on a single estimated glomerular filtration rate
(eGFR) reading of <30 mL/min/1.73 m2 in the 3 months prior to recruitment) and not receiving renal
replacement therapy. A detailed description of the rationale, design and preliminary results has
been published previously [15]. Participants were recruited through their treating physicians and
attended a baseline clinic between February 2016 and September 2018. Individuals with at least one
medication and who agreed to participate in an additional medication interview were included in the
current analysis.
At baseline, participants attended a study clinic where a range of sociodemographic, clinical,
laboratory and HRQOL information was collected by the research nurse. Consenting participants
were then contacted by a research pharmacist (WHT) to arrange an additional interview regarding
participants’ medications and medication-taking behaviour. At follow-up (at least a year after the
baseline assessment), participants attended a clinic for an additional interview (between August 2017
and October 2018). This study was approved by the Tasmanian Health and Medical Human Research
Ethics Committee (H0015099).
2.2. Measures
Medication-Related Factors
Medication-related information collected from participants during the baseline interview was
verified using electronic health records. To determine actual medication burden, the validated 65-item
medication regimen complexity index (MRCI) [16] and simple medication count were used. Perceived
burden of medication (PBM), a tool previously developed and validated in adults with ESKD, was
used to assess participants’ perceived burden of their medication regimens [11]. This tool consists of
six Likert-scale questions asking if patients feel bothered by the number of medications they take, the
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size of the pills, adverse effects of medications, the dosing frequency, the need to take medications at
work or in social contexts, and the need to drink fluid to take medications.
Medication adherence was self-reported by participants at baseline using the
Morisky-Green-Levine Scale (MGLS). [17] This scale consists of four questions with ‘yes/no’ answers,
with patients deemed nonadherent if they respond ‘yes’ on at least one of the questions. The Tool for
Adherence Behaviour Screening (TABS), a questionnaire developed in Australia to assess adherence
behaviour in adults taking chronic medications [18], was also used during the interview. This tool
assesses both intentional and unintentional nonadherence, and has two subcomponents: one for
‘adherence’ and one for ‘nonadherence.’ The subcomponents have four items each; a differential score
(i.e., total for ‘adherence’ minus total for ‘nonadherence’) of ≥15 reflects good adherence and of ≤14
indicates suboptimal adherence [19].
2.3. Covariates
Patient characteristics, including age, gender, marital status, level of education and means of
income, and smoking history (current/former vs. never), were recorded at baseline. An index of
Socioeconomic Disadvantage was retrieved using the postcode of participants from the Socio-Economic
Indexes for Areas of the Australian Bureau of Statistics [20]. The modified Charlson’s Comorbidity
Index (CCI) [21], calculated using medical conditions as reported by the participant’s treating physician,
was used to determine the medical comorbidities. Baseline laboratory values, including haemoglobin,
eGFR and serum creatinine, were extracted using electronic records. eGFR was calculated using the
CKD Epidemiology Collaboration (CKD-EPI) equation [22].
Participants self-reported their level of functionality using the basic Activities of Daily Living
(ADL) [23] and Instrumental Activities of Daily Living (IADL) [24]. The ADL assesses the ability to
perform six basic self-care tasks independently, with scores ranging between 0 and 6 for low to high
level of functioning. The IADL assesses functionality to deal with more complex tasks, including the
handling of finances and managing medications. This tool contains eight items ranging from 0, for
highly dependent individuals, to 8, for those who are increasingly independent. Treating physicians
also rated the functionality of the participants using the Karnofsky Performance Scale [25]. Scores range
between 0 and 100, with higher scores corresponding to greater performance. Participants self-reported
their desire for autonomy using the Autonomy Preference Indexes. This tool includes an eight-item
decision-making (preference to be involved in decision-making) and a six-item information-seeking
(desire to be informed) scales. Each of these scales were then standardised into scores ranging between
0 and 100 [26]. Zero indicates low preference for autonomy (i.e., delegating to healthcare professionals),
while 100 indicates a strong preference and 50 a neutral attitude [26,27]. Cognitive functioning was
objectively measured using the Montreal Cognitive Assessment (MOCA), with scores ≥ 26 indicating
good cognitive functioning [28]. The Patient Health Questionnaire, a nine-item diagnostic tool, was
used to assess the presence of depression [29].
HRQOL was self-reported by participants at baseline and at follow-up using the Kidney Disease
Quality of Life Short-Form health survey (KDQOL-36) [30]. This tool consists of a combination of
kidney disease-targeted items and generic items. The disease-specific part consists of eleven domains
including two dialysis related domains. Therefore, nine domains assessing symptoms, effects, burden,
work status, cognitive function, social interaction, sexual function, sleep and social support were
applicable to this cohort. Participant responses were transformed into a 100-point scale, with higher
scores reflecting better health. The short form (SF-36) is a 36-item questionnaire that assesses eight
generic health domains, comprising physical functioning, physical role limitations, pain, general health,
vitality, social functioning and mental health. These domains are then aggregated into two component
summary scores; physical health (PCS) and mental health component summaries (MCS), with higher
scores reflecting greater self-reported HRQOL. Change in HRQOL was examined using the difference
between baseline and follow-up MCS and PCS scores, with score differences of ≥5 considered clinically
significant [12].
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3. Statistical Analyses
Variables were checked for normality of distribution via visual inspection of histograms.
Normally-distributed continuous variables were reported as mean ± standard deviation (SD), and
nonnormally-distributed variables were reported as median (interquartile range [IQR]). Frequency
(percentage) was used to report proportions.
Participant characteristics were compared with respect to medication adherence (yes/no). Student’s
t-test was used to compare continuous variables with a normal distribution, while Mann Whitney-U
test was applied for nonnormally distributed variables. Chi-square test was used for comparison of
categorical variables. Factors associated with medication nonadherence were examined using binary
logistic regression, with effect sizes reported using odds ratios (ORs) and 95% confidence intervals
(CIs). Factors were included in the final model based on a p-value < 0.1 on univariate analyses or
set a priori based on clinical importance and previous research [2,11,12]. The decision-making and
information-seeking scales were treated in these analyses both as continuous and categorical variables.
A cut-off point of 50 was used for categorising decision-making and information-seeking scales, as this
score is considered to show neutrality in terms of increased preference for participation in one’s care as
opposed to delegating it to healthcare professionals [26]. To identify factors associated with actual and
perceived medication burden, linear regression models were utilised, with associations reported using
coefficients (β) and 95% CIs.
Finally, changes in different HQROL measures at baseline and follow-up were compared using
a paired t-test. Associations between medication nonadherence (MGLS) and changes in different
HRQOL measures were performed using linear regression models, with analyses adjusted for age,
gender and baseline eGFR. Clinically significant changes in physical (PCS) and mental (MCS) quality of
life measures were compared by adherence status using a Chi-square test. The median (IQR) changes in
PCS and MCS over the follow-up period are illustrated using boxplots. A p < 0.05 was set to determine
statistical significance. STATA version 15.1 software (StataCorp LLC, College Station, TX, USA) was
used for analysis.
4. Results
Overall, 464 eligible individuals were invited to participate in the study (Figure 1). Of these,
132 (28%) attended a baseline study clinic appointment and 101 (21%) participated in an additional
medication interview. Subsequently, 63 (62%) of these participants completed the follow-up interview.
Participants at baseline were predominantly men (67%), with a mean age and eGFR of 72 (SD 11) years
and 21 (SD 6) mL/min/1.73 m2, respectively. Participants were not different from nonparticipants in
terms of age and Index of Socioeconomic Disadvantage (p > 0.05). However, a higher proportion of
nonparticipants were women (52% vs. 32%, respectively; p = 0.04).
Overall, 79% of the participants were taking ≥ 5 medications at baseline and 43% were taking ≥ 9
medications. Based on the MGLS, about 43% of the participants were considered nonadherent, while
60% reported suboptimal adherence based on TABS. API scores revealed that while most participants
were interested in having more information (mean API information-seeking; 82 ± 11), they preferred
healthcare professionals to make decisions for them (mean API decision-making; 45 ± 17). The baseline
characteristics of participants by medication adherence are described in Table 1.
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Figure 1. Flow diagram of the recruitment process. 
Table 1. Characteristics of participants by medication adherence (n = 101). 
 Adherence (MGLS) Adherence (TABS) 
Variables 
Total  
(n = 101) 
Yes  
(n = 58) 
No (n = 43)  p 
Yes  
(n = 40) 
No 
(n = 61) 
p 
Sociodemographic 
Age (years) 72 (11) 73 (11) 70 (11) 0.12 74 (11) 70 (11) 0.06 
Male gender, n (%)  68 (67) 36 (53) 32 (47) 0.19 31 (46) 37 (54) 0.08 
Level of education (year 12 or less), n (%) 63 (62) 38 (60) 25 (40) 0.45 26 (41) 37 (59) 0.66 
Married/de facto, n (%) 65 (49) 36 (55) 29 (45) 0.58 27 (41) 38 (59) 0.59 
Government pension, n (%) 64 (63) 37 (58) 27 (42) 0.6 27 (42) 37 (58) 0.67 
Index of Disadvantage (highest quartile) 33 (33) 19 (58) 14 (42) 0.3 11 (33) 22 (67) 0.47 
Autonomy preference index        
Decision-making 45 (17) 42 (15) 49 (18) 0.04 41 (13) 47 (18) 0.1 
Information-seeking 82 (11) 83 (11) 82 (11) 0.78 82 (11) 83 (11) 0.74 
Karnofsky performance scale 87 (10) 86 (8) 88 (12) 0.54 87 (9) 86 (12) 0.65 
Major depression (PHQ-9 score ≥ 10) 12 (12) 5 (42) 7 (58) 0.24 6 (50) 6 (50) 0.61 
Clinical 
Smoking (former/current), n (%) 51 (50) 29 (57) 22 (43) 0.91 23 (45) 28 (55) 0.25 
Comorbidity index, median (IQR) 3 (1–4) 3 (1–5) 2 (1–3) 0.38 3 (2–4) 2 (1–3) 0.04 
Common comorbidities, n (%)        
Hypertension 90 (94) 52 (58) 38 (42) 0.71 38 (42) 52 (58) 0.67 
Diabetes mellitus 39 (40) 28 (72) 11 (28) 0.02 13 (33) 26 (67) 0.19 
Atherosclerotic disease 36 (37) 20 (56) 16 (44) 0.74 18 (50) 18 (50) 0.18 
Figure 1. Flow diagram of the recruitment process.
Table 1. Characteristics of participants by medication adherence (n = 101).
Adherence (MGLS) Adherence (TABS)
Variables Total(n = 101)
Yes
(n = 58)
No
(n = 43) p
Yes
(n = 40)
No
(n = 61) p
Sociodemographic
Age (years) 72 (11) 73 (11) 70 (11) 0.12 74 (11) 70 (11) 0.06
Male gender, n (%) 68 (67) 36 (53) 32 (47) 0.19 31 (46) 37 (54) 0.08
L vel of education (year 12 or less), n (%) 63 (62) 8 (60) 25 (40) 0.45 26 (41) 37 (59 6
Married/de facto, n (%) 65 (49) 36 (55) 29 (45) 0.58 27 (41) 38 (59) 0.59
Government pension, n (%) 64 (63) 37 (58) 27 (42) 0.6 27 (42) 37 (58) 0.67
Index of Disadvantage (highest quartile) 33 (33) 19 (58) 14 (42) 0.3 11 (33) 22 (67) 0.47
Autonomy preference index
Decisio -making 45 (17) 42 (15) 49 (18) 0.04 41 (13) 47 (18) 0.1
Information-seeking 82 (11) 83 (11) 82 (11) 0.78 82 (11) 83 (11 74
Karnofsky performance scale 87 (10) 86 (8) 88 (12) 0.54 87 (9) 86 (12) 0.65
Major depression (PHQ-9 score ≥ 10) 12 (12) 5 (42) 7 (58) 0.24 6 (50) 6 (50) 0.61
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Table 1. Cont.
Adherence (MGLS) Adherence (TABS)
Variables Total(n = 101)
Yes
(n = 58)
No
(n = 43) p
Yes
(n = 40)
No
(n = 61) p
Clinical
Smoking (former/current), n (%) 51 (50) 29 (57) 22 (43) 0.91 23 (45) 28 (55) 0.25
Comorbidity index, median (IQR) 3 (1–4) 3 (1–5) 2 (1–3) 0.38 3 (2–4) 2 (1–3) 0.04
Common comorbidities, n (%)
Hypertension 90 (94) 52 (58) 38 (42) 0.71 38 (42) 52 (58) 0.67
Diabetes mellitus 39 (40) 28 (72) 11 (28) 0.02 13 (33) 26 (67) 0.19
Atherosclerotic disease 36 (37) 20 (56) 16 (44) 0.74 18 (50) 18 (50) 0.18
Congestive heart failure 17 (18) 7 (41) 10 (59) 0.12 9 (53) 8 (47) 0.27
Peripheral vascular disease 13 (13) 6 (46) 7 (54) 0.37 8 (61.5) 5 (38.5) 0.11
Malignant neoplasm 20 (21) 14 (70) 6 (30) 0.22 13 (65) 7 (35) 0.01
Body mass index, kg/m2 30 (6) 31 (6) 30 (5) 0.67 28 (26–31) 32 (27–35) 0.02
ADL 5.8 (0.4) 5.9 (0.3) 5.7 (0.5) 0.1 5.8 (0.4) 5.8 (0.4) 0.36
IADL 5.5 (1.4) 5.5 (1.4) 5.2 (1.1) 0.06 5.4 (1.4) 5.6 (1.5) 0.34
Cognitive impairment (MOCA < 26), n (%) 65 (67) 41 (72) 24 (60) 0.22 23 (35) 42 (65) 0.17
Laboratory
Haemoglobin (g/L) 119 (18) 117 (15) 121 (22) 0.3 119 (20) 119 (17) 0.99
Serum creatinine (µmol/L) 265 (112) 249 (101) 288 (122) 0.03 266 (101) 265 (119) 0.97
eGFR (mL/min/1.73 m2) 21 (7) 22 (6) 21 (7) 0.51 21 (7) 21 (6.5) 0.89
Medical
No. of medications, median (IQR) 8 (6–11) 8 (6–11) 8 (6–11) 0.73 8 (5–11) 8 (6–10) 0.73
MRCI, median (IQR) 19 (14–27) 20 (9–28) 17 (14–27) 0.41 19 (17–27) 19 (14–27) 0.76
PBM, median (IQR) 1.17(1–1.33) 1 (1–1.33)
1.33
(1–1.33) 0.01 1 (1–1.33)
1.33
(1–1.33) 0.04
HRQOL (SF-36)
PCS 39 (10) 39 (10) 39 (10) 0.65 39 (10) 39 (10) 0.96
MCS 51 (10) 51 (9) 50 (11) 0.62 51 (10) 51 (10) 0.96
Abbreviations: ADL, activities of daily living; BMI, body mass index; CCI, Charlson’s comorbidity index; eGFR,
estimated glomerular filtration rate; IADL, instrumental activities of daily living; IQR, interquartile range; MCS,
mental component summary; MGLS, Morisky Green Levine Scale; MOCA, Montreal cognitive assessment; PBM,
perceived burden of medication; PCS, physical component summary; PHQ-9, 9-item patient health questionnaire;
SD, standard deviation; TABS, Tool for Adherence Behaviour Screening. Results are presented in mean (SD) unless
described otherwise.
4.1. Factors Associated with Medication Nonadherence
Table 2a shows the effect of medication burden and other factors associated with medication
nonadherence. People who reported nonadherence were more likely to report higher perceived
medication burden (OR 4.89; 95% CI 1.02–23.5; p = 0.02) after adjusting for age, gender, eGFR,
comorbidity and IADL. Actual medication burden (the number of medications and MRCI) was not
associated with nonadherence. People with a high desire for decision-making were 4.6 times more
likely to report nonadherence compared with those who prefer to delegate decisions to healthcare
professionals (adjusted OR 4.56 95% CI 1.68–12.35). Participants with diabetes were more likely to
self-report being adherent (adjusted OR 0.36; 95% CI 0.14–0.89).
We also examined factors associated with suboptimal medication adherence assessed by the
TABS (Table 2b). Both actual and perceived medication burden were not related to TABS adherence
measurement. However, participants with high BMI (≥30 kg/m2) were more likely to be nonadherent
compared with those with normal BMI after adjusting for age, gender, CCI and eGFR (OR 3.81; 95%
CI 1.01–14.5).
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Table 2. Correlates of medication nonadherence.
a. Nonadherence (MGLS) Unadjusted ORs (95% CIs) Adjusted ORs (95% CIs) *
No. of medications 0.97 (0.87–1.08) 0.96 (0.85–1.07)
MRCI (cont.) 0.83 (0.55–1.26) 0.89 (0.56–1.44)
PBM (cont.) 4.02 (1.03–16) 4.89 (1.02–23.5)
Having diabetes 0.37 (0.15–0.91) 0.36 (0.14–0.89)
Decision making (cont.) 1.11 (1.001–1.23) 1.15 (1.02–1.29)
Decision-making (cat; score > 50) 3.29 (1.41–7.69) 4.56 (1.68–12.35)
b. Nonadherence (TABS) Unadjusted ORs (95% CIs) Adjusted ORs (95% CIs)
No. of medications 1.02 (0.91–1.13) 1.04 (0.92–1.18)
MRCI (cont.) 1.003 (0.96–1.05) 1.01 (0.96–1.06)
PBM (cont.) 3.67 (0.84–16.1) 2.78 (0.53–14.5)
BMI (≥30 kg/m2) 2.85 (0.21–2.6) 3.81 (1.01–14.5)
API, Autonomy preference index; Cat., categorical; CIs, confidence intervals; Cont., continuous; MGLS, Morisky
Green Levine Scale; PBM, Perceived burden of medications; ORs, odds ratios. * Analysis adjusted for age, gender,
eGFR, Charlson’s comorbidity index and IADL.
4.2. Factors Associated with Perceived and Actual Medication Burden
Given the strong association between perceived medication burden and medication nonadherence,
we further explored factors associated with PBM (Table 3a). A higher number of medications (β 0.02;
95% CI 0.01 to 0.04) and MRCI scores (β 0.10; 95% CI 0.03 to 0.15) predicted higher perceived medication
burden. Additionally, a more frequent dosing interval was associated with higher perceived burden
on adjusted analysis (β 0.02; 95% CI 0.01 to 0.03). After adjustment for gender, eGFR, CCI and IADL,
increasing age was associated with lower perceived burden from medications (β −0.01; 95% CI −0.014
to −0.004). An increased desire for decision-making (β 0.02; 95% CI 0.01 to 0.03) and a higher desire for
information (β 0.02; 95% CI 0.01 to 0.04) were also associated with higher perceived burden.
Table 3. Correlates of perceived and actual medication burden.
a. Perceived Medication Burden (PBM)—Continuous
Variables Unadjusted β (95% CIs) Adjusted β (95% CIs)
No. of medications 0.02 (0.01, 0.04) 0.02 (0.01, 0.04)
MRCI (cont.) 0.08 (0.02, 0.14) 0.10 (0.03, 0.15)
Dosage form 0.023 (−0.001, 0.05) 0.024 (−0.001, 0.05)
Dosing frequency 0.02 (0.01, 0.03) 0.02 (0.01, 0.03)
Additional instructions 0.01 (−0.01, 0.02) 0.01 (−0.01, 0.03)
Age (cont.) −0.01 (−0.014, −0.004) −0.01 (−0.015, −0.005)
API Decision-making (cont.) 0.02 (0.01, 0.03) 0.02 (0.01, 0.03)
API Information-seeking (cont.) 0.02 (0.01, 0.04) 0.02 (0.01, 0.04)
b. Actual Medication Burden (MRCI)—Continuous
Variables Unadjusted β (95% CIs) Adjusted β (95% CIs)
No. of medications 2.44 (2.26, 2.63) 2.49 (2.31, 2.67)
Having diabetes 7.31 (3.57, 11.1) 7.54 (3.43, 11.6)
Kidney disease-targeted scales
Symptom −0.26 (−0.38, −0.15) −0.25 (−0.37, −0.17)
Effects of kidney disease −0.19 (−0.34, −0.06) −0.23 (−0.39, −0.08)
Burden of kidney disease −0.12 (−0.19, −0.04) −1.64 (−0.25, −0.08)
Work status −0.09 (−0.15, −0.04) −0.09 (−0.14, −0.03)
SF-36 generic scales
MCS −0.15 (−0.35, 0.04) −0.21 (−0.43, −0.01)
PCS −0.43 (−0.61, −0.26) −0.44 (−0.62, −0.26)
API, autonomy preference index; MRCI, medication regimen complexity index; MCS, mental component summary;
PCS, physical component summary; SF-36, 36-item short form survey. Analysis adjusted for age, gender, Charlson’s
comorbidity index, activities of daily living (IADL) and cognitive functioning (MOCA).
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To examine whether factors associated with perceived medication burden were different from
those affecting actual medication burden, we investigated the correlates of MRCI (Table 3b). As
expected, patients with diabetes had a more complex medication regimen (β 7.54; 95% CI 3.43 to
11.6). Lower physical (SF36-PCS) (β −0.43; 95% CI −0.62 to −0.26) and mental HRQOL (SF36-MCS)
(β −0.21; 95% CI −0.43 to −0.01) at baseline were associated with higher medication burden (MRCI).
An inverse association was also observed between kidney disease-targeted HRQOL scales, such as
disease symptoms, burden, work status and effects of the disease and medication burden.
4.3. Changes in HRQOL and Its Association with Medication Nonadherence
The mean ± SD follow-up time for participants who completed the second interview was
433 ± 82 days (~14 months), with no difference in follow-up duration observed between adherent vs
nonadherent groups (436 ± 88 vs. 430 ± 77 days; p = 0.76)
The changes in different components of HRQOL, both kidney disease-targeted and generic SF-36
scales, are presented in the Appendix A attached. Follow-up data were completed by 63 and 60
participants for kidney-disease targeted scales and generic SF-36 scales, respectively. Out of the
disease-targeted components, only the burden of kidney disease showed a significant change at
follow-up (mean ± SD score declined from 77 ± 25 to 70 ± 31; p = 0.01). Overall, there was no
association between medication adherence and changes in kidney disease-targeted scales over time.
Of the 60 participants with completed generic HRQOL data (SF-36), a decline of any magnitude
in physical and mental HRQOL was observed in 58% at around 14 months of follow-up. A clinically
significant decline in physical HRQOL (change in SF36-PCS ≤ 5) was observed in 35% of participants
overall, representing 26% of adherent and 45% of nonadherent participants (p = 0.20). A significant
reduction in mental HRQOL was also observed in 35% of participants overall, which represented 42%
of adherent and 28% of nonadherent individuals (p = 0.16).
As illustrated in Figure 2, the physical HRQOL was improved over time in adherent individuals
compared with a decline in their nonadherent counterparts (a median [IQR] change in PCS of 1.5 [−5.3,
7.6] vs. −3.4 [−9.1, 0.9]; p = 0.06). Further, medication nonadherence showed a significant negative
association with a change in physical HRQOL after adjusting for age, gender and baseline eGFR
(β −4.64; 95% CI −9.10, −0.17) (Table 4). There was no association between medication nonadherence
and change in mental HRQOL before or after adjustment for the same variables.
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Table 4. Association between medication nonadherence (MGLS) and changes in physical and mental
health-related quality of life health over time.
Unadjusted β (95% CIs) Adjusted β (95% CIs) *
SF36-PCS
Nonadherence −3.99 (−8.29, 0.31) −4.64 (−9.10, −0.17)
SF36-MCS
Nonadherence 1.82 (−3.12, 6.78) 2.03 (−2.99, 7.05)
* analyses adjusted for age, gender and baseline eGFR.Abbreviations: CIs, confidence intervals; MGLS, Morisky
Green Levine Scale; SF36-PCS, short form physical component summary; SF36-MCS, short form mental component
summary; physical component summary.
5. Discussion
This study indicates that a considerable proportion of adults with predialysis CKD are nonadherent
to their medications. The 43% medication nonadherence (MGLS) was lower than that reported by
an Australian study on dialysis patients that used the same questionnaire, where 57% of participants
were nonadherent [10]. This is understandable, given the relatively higher degree of medical
complexity in dialysis patients compared to those in the earlier stages of CKD [10,31]. Of note, a greater
proportion of suboptimal adherence (60%) was identified via the TABS questionnaire. This could
relate to the differences in the constructs of the two questionnaires [16,17]. In addition to medication
adherence, the TABS, for example, also captures patients’ experiences and behaviour concerning
disease management [18]. This shows that medication nonadherence is multidimensional in nature
and needs different strategies to detect in patients with predialysis CKD.
Importantly, perceived burden (PBM) of medications, not the actual burden, was associated with
medication nonadherence. The association between PBM and nonadherence is in contrast with a prior
Australian study that showed no relationship between these factors [10]. A study from Italy showed
that perceived burden can modulate the relationship between medication regimen complexity and
adherence in dialysis patients [11]. In this study, Neri et al. found that each pill that was added to
a regimen of a patient with low PBM was associated with a 5% increase in the odds of nonadherence [11].
This was not the case in those with high PBM, where regimen complexity was not associated with
nonadherence [11]. The findings highlight the need to evaluate the perceived burden, alongside actual
medication burden, to optimise adherence. Also, simplifying a medication regimen may not effectively
improve adherence unless patients’ perceptions are concomitantly addressed [11].
Another interesting result from this study was that people with an increased desire for autonomous
decision-making were more likely to be nonadherent. This corresponds with a finding from a study
on patients with asthma that applied the same set of questionnaires [32]. The relationship between
desire for decision-making and nonadherence could relate to intentional nonadherence, where patients
make a conscious decision to skip medications. This phenomenon has been explained by a qualitative
review that identified ‘rationalised nonadherence’ as a mechanism used by patients to avoid treatment
disruptions of their daily routine [33]. A similar finding was reported in dialysis recipients where
people tended to consciously overlook treatments, which the authors termed ‘active nonadherence’ [34].
This is particularly common with medications they considered less important or less easy to adhere
to [34]. Therefore, there is a need to foster optimal patient-centred care to actively engage patients in
conversations that enable them to acknowledge medication-related difficulties in view of improving
adherence [33]. Reiterating the importance of medications in slowing disease progression at the point
of care could also help improve adherence. Finally, obese participants (BMI ≥ 30 kg/m2) were more
likely to be nonadherent than people with normal BMIs based on the TABS. The relationship between
higher BMI and poor adherence has been reported in older men previously [35]. This association could
be because nonadherence in these individuals might also extend to exercise or dietary restrictions [35].
Highly complex regimens and more frequent dosing were associated with higher perceived
medication burden, while older age was associated with feeling lower burden. The association
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of regimen complexity and more frequent dosing with perceived treatment burden has been
reported [36,37]. These factors are important given their practical relevance and the relative ease with
which they may be targeted by interventions seeking to reduce medication burden [36]. For instance,
the use of long-acting alternatives instead of the repeated use of immediate-release medications is
one strategy that can reduce the dosing frequency. Nevertheless, it is important to understand that
even less complex regimens could prove burdensome in some patients [37]. Particularly, patients with
limited cognitive functionality or with little support could be affected in this regard. The association
between older age and lower perceived treatment burden is in line with prior studies [11,36,37]. This
may be associated with older people’s adaptation to medications after long-term use [36]. Older adults
may also consider their medications more a matter of necessity rather than a burden [36].
Lower HRQOL (kidney disease-targeted and generic scales) were predictive of actual medication
burden (MRCI). The association between HRQOL measures and regimen complexity was independent of
Charlson’s comorbidity score, suggesting that regimen complexity may capture additional information
on the overall disease status of patients [31]. This may also strengthen our prior hypothesis, i.e., that
regimen complexity could serve as a proxy measure of overall health in patients with CKD [38]. Also,
an inverse relationship between medication burden and HRQOL has been previously reported in
predialysis patients with CKD [13].
Medication nonadherence was not associated with baseline HRQOL; however, it was associated
with a decline in physical, but not mental, HRQOL (SF36-PCS) over time. This finding was despite
the significant decline in mental HRQOL during follow-up for all participants. A study from the
AusDiab cohort previously reported that a physical decline in HRQOL is dependent on baseline
eGFR values [12]. However, we found no association between baseline eGFR and changes in HRQOL
over time.
This study has some strengths and weaknesses. Examining people with advanced CKD not
receiving renal replacement therapy adds a new perspective to the literature, as patient-reported
medication experiences in this patient group are currently lacking. This is also the first study to examine
the association between medication nonadherence and a change in HRQOL over time in patients with
CKD. The inclusion of in-depth patient, clinical, medication and social factors is another strength
of this study. The relatively small number of participants included may limit the generalisability
of the study; however, recruiting people with relatively poorer health and lower functional status
is difficult [15]. The use of self-report, but not objective measures, to assess adherence is another
limitation of the study, as nonadherent behaviour is often under-reported due to social desirability bias.
However, self-reported adherence measures have an advantage in terms of ease of implementation in
real practice. In addition, the self-report measures applied in this study capture both intentional and
unintentional adherence.
6. Conclusions
This study indicates that medication nonadherence is common in adults with predialysis CKD.
Perceived medication burden was a predictor of nonadherence, highlighting the need to incorporate
patient-reported medication experiences in routine CKD care. Further, while medication regimen
complexity was negatively associated with both physical and mental HRQOL at baseline, nonadherence
was associated with a decline in physical HRQOL over time. This finding suggests the potential role of
medication-related factors in modifying patient-centred outcomes and the need for further research to
better understand this relationship.
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Appendix A
This appendix contains the change in different disease-specific and generic components over time,
as assessed by KDQOL-36.
Table A1. Health-related quality of life (HRQOL) measures at baseline and at 14-months follow-up
(KDQOL-SF36), the Tasmanian Chronic Kidney Disease study.
HRQOL Scales All Participants(n = 101)
Participants with
Follow-Up Data
Kidney Disease-Related
Scales (n = 63) Baseline Follow-Up p-Value *
Burden of kidney disease 75 (24) 77 (25) 70 (31) 0.01
Symptoms 79 (16) 78 (16) 77 (15) 0.59
Cognitive function 81 (16) 81 (15) 79 (16) 0.45
Effect of kidney disease 88 (13) 88 (14) 86 (17) 0.19
Sleep 64 (19) 62 (20) 62 (22) 0.80
Social interaction 82 (15) 82 (15) 82 (15) 0.89
Social support 83 (25) 87 (22) 82 (27) 0.18
Work status 43 (34) 42 (33) 41 (35) 0.64
Overall health status 63 (18) 62 (19) 59 (19) 0.08
SF-36 scales (n = 60)
Physical function 56 (26) 56 (26) 55 (30) 0.78
Physical role limitations 47 (42) 49 (39) 36 (38) 0.01
Pain 60 (28) 64 (27) 60 (28) 0.13
General health 49 (29) 46 (20) 44 (21) 0.29
Emotional well-being 79 (22) 77 (18) 76 (19) 0.57
Emotional role limitations 70 (40) 77 (36) 65 (38) 0.02
Social function 77 (30) 77 (26) 68 (29) 0.004
Vitality 55 (27) 48 (23) 45 (24) 0.22
SF36-PCS 38 (10) 38 (11) 37 (11) 0.22
SF36-MCS 51 (11) 52 (11) 49 (11) 0.03
Abbreviations: SF-36, 36-item short form survey; MCS, mental component summary; PCS, physical; component
summary; * Paired t-test; Results are in mean (SD).
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